During the COVID-19 pandemic, the US Food and Drug Administration expanded its use of remote regulatory assessments (RRAs), which allowed the agency to keep its eyes on facilities without investigators having to go on-site.
Based on its experience using RRAs amid the pandemic, the FDA has concluded it should keep the remote technology in...






